M Helena Garcia
Universidade de Lisboa, Portugal
Title: Ruthenium organometallic compounds as promising anti-metastatic drugs for breast cancer chemotherapy
Biography
Biography: M Helena Garcia
Abstract
Ruthenium complexes are the most widely studied non-platinum metallodrugs and hold great potential as alternatives in cancer therapy. During the recent years our group has been putting a significant effort on the synthesis of new half sandwich “Ru(5-C5H5)” derived compounds which cytotoxicity was found, in most of the cases, better than that of cisplatin against several cancer cell lines of typically low, medium and high resistance to metallodrugs. Our studies in vivo involving triple negative breast cancer (TNBC) tumors showed that our Lead compound had the dual capacity to inhibit the development of metastasis and to suppress significantly the tumour growth. We will report here our progressing studies concerning our Lead drug, such as uptake and cell death mechanisms, modulation, biodistribution, blood speciation, just to give some examples, considered crucial to the progression of our drug into clinical evaluation. Our gathered results indicate so far the relevance of this new family of half sandwich compounds as potential anticancer agents with particular importance for TNBC for which there is not available in clinic any efficient chemotherapeutic agent.
